VEXAS Syndrome: an Updated Literature Review

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a newly described autoinflammatory disease with various manifestations mimicking myelodysplastic syndrome, vasculitis, and neutrophilic dermatosis, affecting males over 50 years old. The etiology is an acquired error of innate immunity due to a somatic mutation in the ubiquitylation-controlling gene UBA1, resulting in an aberrant inflammatory process. Although there is no specific therapy for VEXAS syndrome, many agents including cyclophosphamide, anti-IL-6, and Janus kinase (JAK) inhibitors have been tried, with varying results so far. Hereby, a literature review is presented, summarizing the current knowledge regarding the pathogenesis, clinical manifestations, and treatment options for VEXAS syndrome.Cite this article as: Kottas K, Faltaka A, Katsifis G. VEXAS syndrome: an updated literature review. Eur J Rheumatol. 2025, 12(3), 0096, doi:10.5152/ eurjrheum.2025.24096.

Institutions

Publication Details

Journal
European Journal of Rheumatology
Published
2025-10-27
DOI
https://doi.org/10.5152/eurjrheum.2025.24096
Primary Topic
Otitis Media and Relapsing Polychondritis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

VEXAS Syndrome: an Updated Literature Review

European Journal of Rheumatology
Otitis Media and Relapsing Polychondritis
article

VEXAS Syndrome: an Updated Literature Review

article en

Abstract

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a newly described autoinflammatory disease with various manifestations mimicking myelodysplastic syndrome, vasculitis, and neutrophilic dermatosis, affecting males over 50 years old. The etiology is an acquired error of innate immunity due to a somatic mutation in the ubiquitylation-controlling gene UBA1, resulting in an aberrant inflammatory process. Although there is no specific therapy for VEXAS syndrome, many agents including cyclophosphamide, anti-IL-6, and Janus kinase (JAK) inhibitors have been tried, with varying results so far. Hereby, a literature review is presented, summarizing the current knowledge regarding the pathogenesis, clinical manifestations, and treatment options for VEXAS syndrome.Cite this article as: Kottas K, Faltaka A, Katsifis G. VEXAS syndrome: an updated literature review. Eur J Rheumatol. 2025, 12(3), 0096, doi:10.5152/ eurjrheum.2025.24096.

European Journal of RheumatologyVol. 12(3)
Athens Naval & Veterans Hospital (GR)
Good health and well-being
Openalex Percentile: Top 33%
Otitis Media and Relapsing Polychondritis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.